So, both Yang et al. [55] and Zhang et al. [56] demonstrate that CCL3 is a critical enhancer of CD8+ T-cell-mediated anti-tumor responses and a key determinant of the therapeutic efficacy of PD-1 immune checkpoint blockade, revealing the anti-tumor effects of CCL3. This evidence concerns the gene CD8A and neoplasm.